Business Context and Reporting Period
This Form 8-K is a current report filed by NanoVibronix, Inc. (trading symbol: NAOV) on January 13, 2022. The filing addresses corporate governance changes, specifically the expansion of the Board of Directors. Note: The request metadata references "Envue Medical, Inc.," but the provided filing text explicitly identifies the registrant as NanoVibronix, Inc.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is limited to reporting the appointment of new directors.
Material Changes
- Board Expansion: The Board of Directors increased in size from six to eight members.
- New Appointments: Aurora Cassirer and Maria Schroeder were appointed as independent directors effective January 13, 2022.
- Committee Assignments:
- Aurora Cassirer: Compensation Committee and Nominating and Governance Committee.
- Maria Schroeder: Audit Committee.
- Term: Both directors serve until the 2022 annual meeting of stockholders or until their successors are appointed.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It confirms that there are no undisclosed arrangements or transactions between the new directors and the company requiring disclosure under Item 404(a) of Regulation S-K.
Key Facts for Investor Verification
- Verify the trading symbol NAOV corresponds to NanoVibronix, Inc., not Envue Medical, Inc.
- Confirm the new board composition (8 members) and the specific committee roles of the new appointees.
- Review the attached press release (Exhibit 99.1) for additional biographical details on the new directors.
- Note that this filing does not provide any update on the company's financial health or operational progress.